NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.
NV-387 is a broad-spectrum antiviral drug candidate that NanoViricides plans to develop for respiratory viral infections such as RSV, COVID, Long COVID, and Influenza. It has also shown effectiveness in animal models for monkeypox, smallpox, and measles. The successful completion of Phase I clinical trials in healthy volunteers, with no reported adverse events, underscores the safety profile of NV-387. The company is now focused on moving the drug into Phase II human clinical trials, with the monkeypox trial in the DRC being a priority.
The presentation at the NIBA conference provides an opportunity for NanoViricides to update investors on its antiviral platform and the progress of NV-387. The company’s nanomaterial-based approach aims to create targeted antiviral therapies that could address multiple viral threats. The completion of the oral gummies manufacturing is a critical step toward patient dosing, highlighting the company’s readiness to initiate Phase II trials.
NanoViricides is a clinical-stage company specializing in creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is designed as a broad-spectrum antiviral, and the company also has an advanced candidate, NV-HHV-1, for treating herpesvirus infections. The company cannot project an exact date for filing an IND for any of its drugs due to reliance on external collaborators and consultants.
For more information on NanoViricides and its latest updates, visit the company's newsroom at https://ibn.fm/NNVC. The full press release can be accessed at https://ibn.fm/AILOVA.
